ABSTRACT
OBJECTIVE@#To investigate the titer of IgG anti-A/B erythrocyte antibody in vivo of the neonate with hemolytic disease of newborn(HDN), and explore its clinical valua in evaluating the severity of HDN.@*METHODS@#300 neonates with HDN, 50 neonates with neonatal hyperbilirubinemiain and 50 healthy neonates were selected as research object and Microtubes Gel Test was used to detect the titer of IgG anti-A/B erythrocyte antibody in vivo. Their clinical data and their mothers' prenatal examination data were retrospectively analyzed. Three hemolysis tests (direct antiglobulin test, free antibody test and release test), irregular antibody screening, and the titer of IgG anti-A/B blood group antibody was determined by serological method. Red blood cells(RBC), hemoglobin(Hb), reticulocytes(Ret) and nucleated red cells were detected by hematology analyzer. Indirect bilirubin and albumin(Alb) were detected by biochemical analyzer. The relationship between the titer of IgG anti-A/B erythrocyte antibody in vivo and the severity of HDN was analyzed.@*RESULTS@#There were six serological diagnosis modes in the HDN group,the difference between modes was statistically significant (P<0.05). The antibody titer relationship between HDN neonates and pregnant women was positive correlation(r=0.8302). The highest antibody titer of release test and free antibody test were 1∶32 and 1∶2, and the difference was statistically significant（P<0.05）. RBC, Hb and Alb in HDN patients were lower than those in neonatal hyperbilirubinemia patients and healthy neonates (P<0.05), and were negatively relevant with antibody titer in vivo (r=-0.8016). Bilirubin content in HDN patients were higher than those in neonatal hyperbiliru binemia patients and healthy neonates group(P<0.05), and was positively relevant with antibody titer in vivo (r=0.8731). The hospital day in HDN patients was significantly relevant with the antibody titer in vivo (r=0.8547), but not with the age, sex, weight and ABO blood types (P>0.05).@*CONCLUSION@#The detection of antibody titer in HDN patients can be used to evaluate the antibody concentration in vivo, predict the ability of antibody to induce erythrocyte hemolysis, and help to judge the serenrity and prognosis of HDN.
Subject(s)
Female , Humans , Infant, Newborn , Pregnancy , ABO Blood-Group System , Bilirubin , Blood Group Incompatibility , Erythroblastosis, Fetal , Erythrocytes , Hematologic Diseases , Hemolysis , Immunoglobulin G , Retrospective StudiesABSTRACT
AIM: To investigate the effect of lowering intraocular pressure ( IOP ) and side effect of travoprost ( TA ) on phacoemulsification and intraoclular lens ( IOL ) implantation in primary open-angle glaucoma ( POAG) . METHODS: Patients with POAG already received surgery of phacoemulsification and IOL implantation were selected by randomized, single - blind, parallel group trial. TA was applied once a day in 43 patients (43 eyes) of treatment group and brinzolamide was used twice in 43 patients ( 43 eyes ) of control group. All patients were observed for 12wk. IOP, ocular symptom and adverse reaction etc. were observed. RESULTS: The daily average IOP ( mean ± standard deviation) in the treatment group decreased from (24. 20±3.01)mmHg (1mmHg=0.133kPa) to (16.77±2.89)mmHg and that in the control group was from ( 23. 87±3. 47 ) mmHg to ( 18. 81± 3. 07 ) mmHg. IOP pre- and pro-treatment within two groups had significant difference ( P CONCLUSION: It is demonstrated that travoprost is highly effective and safe in reducing IOP in POAG already received surgery of phacoemulsification and IOL implantation.
ABSTRACT
<p><b>OBJECTIVE</b>Trimetazidine (TZM) has been shown to have anti-ischemia properties by optimizing ischemic myocardium metabolism. We evaluated the effect of TZM on myocardial metabolism with Positron Emission Computed Tomography (PET-CT) in patients with ischemic cardiomyopathy.</p><p><b>METHODS</b>TZM (60 mg/d, n = 15) or placebo (n = 15) was randomly applied to ischemic cardiomyopathy patients on top of conventional therapy for 12 months. Color Doppler Flow Imaging (CDFI), (18)F-FDP PET-CT imaging and (99m)Tc-MIBI gated single photon emission computerized tomography (SPECT) imaging were performed at study begin and after 12 months. LVEF with CDFI, summed rest scores (SRS) with SPECT and standard uptake value (SUV) with PET-CT of the segments which were perfusion-metabolism matched and decreased were determined respectively.</p><p><b>RESULTS</b>After 12 months, LVEF of the therapy group was increased from (37.9 +/- 5.0)% to (42.3 +/- 10.4)% (P < 0.05), while the control group increased from (37.9 +/- 4.6)% to (40.1 +/- 5.5)% (P > 0.05); SRSs of the matched segments of the therapy and the control were reduced from 3.9 +/- 1.0 to 2.4 +/- 2.3 (P < 0.01) and 4.0 +/- 0.7 to 2.8 +/- 1.8 (P < 0.05) respectively, while LVEF and SRSs were similar at study begin and after 12 months between these two groups. SUV of myocardial segments classified as myocardial perfusion-metabolism matched was increased from 5.3 +/- 1.5 to 9.8 +/- 4.7 in the therapy group (P < 0.05) and from 5.4 +/- 1.2 to 6.0 +/- 2.3 (P > 0.05) in the placebo group, SUV was significantly higher in the therapy group than that in placebo group after 12 months (P < 0.05).</p><p><b>CONCLUSION</b>SPECT and (18)F-FDG imaging combination could be used to detect the surviving myocardium and chronic trimetazidine treatment could increase the glucose metabolism of ischemic cardiomyocytes in patients with ischemic cardiomyopathy.</p>